🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 19 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 14/11/2002 | 17,57 | 18,06 | 17,31 | 17,46 | -0,80% | 4,27% | 865.600 |
| 13/11/2002 | 17,64 | 18,37 | 17,22 | 17,60 | -0,28% | 6,52% | 822.100 |
| 12/11/2002 | 17,88 | 18,10 | 17,41 | 17,65 | -1,34% | 3,86% | 542.400 |
| 11/11/2002 | 18,11 | 18,55 | 17,81 | 17,89 | -2,77% | 4,09% | 446.300 |
| 08/11/2002 | 18,85 | 19,01 | 18,00 | 18,40 | -3,16% | 5,36% | 439.100 |
| 07/11/2002 | 19,00 | 19,53 | 18,70 | 19,00 | -1,09% | 4,37% | 540.300 |
| 06/11/2002 | 19,08 | 19,30 | 18,76 | 19,21 | +0,84% | 2,83% | 691.300 |
| 05/11/2002 | 17,01 | 19,90 | 17,00 | 19,05 | -8,59% | 17,05% | 2.310.400 |
| 04/11/2002 | 19,67 | 21,60 | 19,67 | 20,84 | +6,22% | 9,81% | 1.294.800 |
| 01/11/2002 | 19,15 | 19,80 | 19,05 | 19,62 | +0,05% | 3,92% | 453.600 |
| 31/10/2002 | 19,86 | 20,30 | 19,28 | 19,61 | -1,01% | 5,14% | 624.800 |
| 30/10/2002 | 19,47 | 20,14 | 19,35 | 19,81 | +2,32% | 4,06% | 451.900 |
| 29/10/2002 | 19,45 | 19,70 | 19,08 | 19,36 | -0,97% | 3,19% | 377.100 |
| 28/10/2002 | 19,39 | 19,87 | 19,10 | 19,55 | +1,19% | 3,97% | 557.700 |
| 25/10/2002 | 19,22 | 19,71 | 18,96 | 19,32 | +0,10% | 3,90% | 509.300 |
| 24/10/2002 | 19,09 | 19,59 | 18,76 | 19,30 | +1,85% | 4,35% | 958.500 |
| 23/10/2002 | 18,31 | 19,05 | 17,70 | 18,95 | +3,21% | 7,37% | 569.000 |
| 22/10/2002 | 18,82 | 19,18 | 18,28 | 18,36 | -2,50% | 4,78% | 321.000 |
| 21/10/2002 | 18,79 | 19,00 | 17,88 | 18,83 | +0,53% | 5,96% | 345.200 |
| 18/10/2002 | 18,51 | 19,04 | 18,17 | 18,73 | -0,64% | 4,70% | 512.800 |
| 17/10/2002 | 18,16 | 18,99 | 18,16 | 18,85 | +4,43% | 4,57% | 601.500 |
| 16/10/2002 | 18,30 | 18,45 | 17,55 | 18,05 | -2,59% | 4,92% | 701.500 |
| 15/10/2002 | 17,50 | 19,43 | 17,45 | 18,53 | +6,86% | 11,31% | 1.413.200 |
| 14/10/2002 | 16,67 | 17,43 | 16,41 | 17,34 | +3,96% | 6,12% | 706.300 |
| 11/10/2002 | 17,21 | 17,55 | 16,22 | 16,68 | +0,00% | 7,73% | 1.040.700 |
| 10/10/2002 | 16,25 | 16,98 | 16,00 | 16,68 | +2,65% | 6,03% | 1.036.400 |
| 09/10/2002 | 17,68 | 17,68 | 15,85 | 16,25 | -8,35% | 10,35% | 1.206.600 |
| 08/10/2002 | 17,86 | 18,19 | 17,10 | 17,73 | +0,91% | 6,10% | 488.100 |
| 07/10/2002 | 17,35 | 18,11 | 17,10 | 17,57 | +1,09% | 5,82% | 478.500 |
| 04/10/2002 | 18,25 | 18,94 | 17,34 | 17,38 | -4,40% | 8,77% | 488.800 |